{"id":608767,"date":"2024-06-07T15:10:38","date_gmt":"2024-06-07T19:10:38","guid":{"rendered":"https:\/\/platohealth.ai\/restoring-our-ubiquitination-machinery-to-overcome-resistance-to-cancer\/"},"modified":"2024-06-08T10:18:04","modified_gmt":"2024-06-08T14:18:04","slug":"restoring-our-ubiquitination-machinery-to-overcome-resistance-to-cancer","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/restoring-our-ubiquitination-machinery-to-overcome-resistance-to-cancer\/","title":{"rendered":"Restoring our ubiquitination machinery to overcome resistance to cancer","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
<\/div>\n

\u201c[\u2026] the identification of ubiquitin-conjugating enzymes like UBE2J1 and the innovative deployment of PROTAC-type androgen receptor degraders are crucial in combating prostate cancer and overcoming therapeutic resistance.\u201d<\/em><\/p>\n

Credit: 2024 Li and Mu.<\/p>\n

\n

\u201c[\u2026] the identification of ubiquitin-conjugating enzymes like UBE2J1 and the innovative deployment of PROTAC-type androgen receptor degraders are crucial in combating prostate cancer and overcoming therapeutic resistance.\u201d<\/em><\/p>\n

BUFFALO, NY- <\/strong>June 7<\/strong>, 2024 \u2013 <\/strong>A new editorial paper was published in Oncoscience<\/u><\/em> (Volume 11<\/u>) on May 6, 2024, entitled, \u201cRestoring our ubiquitination machinery to overcome resistance in cancer therapy<\/u>.\u201d<\/p>\n

In this new editorial, researchers Xiaoling Li <\/em>and Ping Mu<\/em> from the University of Southwestern Medical Center<\/u> discuss the ubiquitin-proteasome system (UPS), which is usually responsible for regulating protein degradation, important for cellular homeostasis, and crucial in cancer progression. Its ability to regulate the stability of proteins that drive cancer growth and survival indicates its potential as a therapeutic target. <\/p>\n

Among the UPS components, ubiquitin-conjugating enzymes, such as ubiquitin-conjugating enzyme E2 J1 (UBE2J1), have emerged as key players in cancer dynamics, especially in prostate cancer (PCa) where therapy resistance is a significant challenge.<\/p>\n

\u201cIn our recent study, through a comprehensive in vivo library screening [2<\/u>], we have identified the role of UBE2J1 in PCa, particularly its involvement in the degradation of the androgen receptor (AR) [3<\/u>].\u201d 
 <\/p>\n

Continue reading: DOI:<\/strong> https:\/\/doi.org\/10.18632\/oncoscience.600<\/u> <\/p>\n

Correspondence to:<\/strong> Ping Mu<\/p>\n

Email:<\/strong> [email protected]<\/a><\/u><\/p>\n

Keywords:<\/strong> androgen receptor, prostate cancer, antiandrogen resistance, UBE2J1, ubiquitination, protein degradation, PROTAC
 <\/p>\n

About<\/strong> Oncoscience<\/em><\/strong>: <\/p>\n

Oncoscience<\/u><\/em> is a peer-reviewed, open-access, traditional journal covering the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. This journal has a special mission: Freeing oncology from publication cost. It is free for the readers and the authors.<\/p>\n

To learn more about <\/strong>Oncoscience<\/em><\/strong>, visit Oncoscience.us<\/u> and connect with us on social media:<\/p>\n

For media inquiries, <\/strong>please contact [email protected]<\/a><\/u>.<\/p>\n

Oncoscience<\/u><\/em><\/strong> Journal Office<\/strong><\/p>\n

6666 East Quaker Str., Suite 1D<\/p>\n

Orchard Park, NY 14127<\/p>\n

Phone: 1-800-922-0957, option 4<\/p>\n

###<\/p>\n

\n
\n
\n
\n
\n

Journal<\/h4>\n

Oncoscience<\/p>\n<\/p><\/div>\n

\n

DOI<\/h4>\n

10.18632\/oncoscience.600 <\/i><\/p>\n<\/p><\/div>\n

\n

Method of Research<\/h4>\n

Commentary\/editorial<\/p>\n<\/p><\/div>\n

\n

Subject of Research<\/h4>\n

People<\/p>\n<\/p><\/div>\n

\n

Article Title<\/h4>\n

Restoring our ubiquitination machinery to overcome resistance in cancer therapy<\/p>\n<\/p><\/div>\n

\n

Article Publication Date<\/h4>\n

6-May-2024<\/p>\n<\/p><\/div>\n<\/div>\n<\/div>\n<\/div>\n